Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

Status and phase

Completed
Phase 1

Conditions

Cystic Fibrosis

Treatments

Drug: VX-121/TEZ/D-IVA

Study type

Interventional

Funder types

Industry

Identifiers

NCT05437120
VX21-121-008

Details and patient eligibility

About

The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with moderate hepatic impairment and in matched healthy participants.

Full description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Enrollment

16 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

Cohort 1: Participants with Moderate Hepatic Impairment

  • Participants will satisfy the criteria for moderate hepatic impairment defined as a Child-Pugh total score of 7 to 9 points at the screening visit
  • Participants will have chronic (≥6 months) documented liver disease

Cohort 2: Matched Healthy Participants

Participants will be matched during screening to participants with hepatic impairment for cigarette smoking habit, age, sex, and weight

Key Exclusion Criteria:

Cohort 1: Participants with Moderate Hepatic Impairment

  • History of febrile illness or other acute illness
  • History of solid organ or bone marrow transplantation
  • History or presence of severe hepatic encephalopathy (Grade >2)
  • Any condition possibly affecting drug absorption
  • Severe portal hypertension
  • Significant renal dysfunction (creatinine clearance <50 milliliter per minute [mL/min] ) estimated according to the method of Cockcroft and Gault at the screening Visit or Day-1

Cohort 2: Matched Healthy Participants

  • History of febrile illness or other acute illness
  • Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

16 participants in 2 patient groups

Cohort 1: Moderate Hepatic Impairment
Experimental group
Description:
Participants with moderate hepatic impairment will receive single dose of VX-121/TEZ/D-IVA .
Treatment:
Drug: VX-121/TEZ/D-IVA
Cohort 2: Matched Healthy Participants
Experimental group
Description:
Healthy participants will receive single dose of VX-121/TEZ/D-IVA.
Treatment:
Drug: VX-121/TEZ/D-IVA

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems